FDA Issues Proposal on Lower-Cost, Generic Biotech Drugs

Share this content:
FDA Issues Proposal on Lower-Cost, Generic Biotech Drugs
FDA Issues Proposal on Lower-Cost, Generic Biotech Drugs

THURSDAY, Aug. 27, 2015 (HealthDay News) -- A proposal for identifying lower-cost generic biotech drugs has been released by the U.S. Food and Drug Administration.

Many newer biotech drugs cost more than $10,000 a year and this class of drugs accounts for nearly 30 percent of all drug spending in the country, according to the Associated Press. Earlier this year, the agency approved the first biosimilar drug, the term for generic biotech drugs.

Under the FDA proposal, all biotech drugs would carry a four-letter code to help doctors and pharmacists distinguish brand name and generic versions, the AP reported. Public comments on the proposal will be accepted for 60 days before the FDA moves to finalize the rule.

Generic biotech drugs have been available in Europe since 2006 and about 20 have been approved there, the AP reported.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »